74 results about "Chronic sinusitis" patented technology

Methods of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject, methods of treating chronic rhinosinusitis (CRS) or chronic rhinosinusitis with nasal polyps (CRSwNP) in a human subject, methods of treating a eustachian tube disorder in a human subject, and devices and systems for performing the methods. A method of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject includes inserting a drug-coated balloon catheter into a target site in a trachea, mainstem bronchus, bronchus intermedius, lobar bronchus, segmental bronchus, or sub-segmental bronchus, wherein the balloon is coated with a coating layer including the therapeutic agent and one or more additives. The therapeutic agent includes paclitaxel, sirolimus, or a derivative thereof. The method includes inflating the balloon to dilate the airway and deliver a therapeutic agent to the airway wall. The method includes deflating the balloon. The method also includes withdrawing the balloon catheter from the target site.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention discloses a chronic sinusitis CT (Computed Tomography) image automatic typing and severity assessment method and a chronic sinusitis CT image automatic typing and severity assessment system based on deep learning. The method comprises the following steps: acquiring paranasal sinus CT image data of a chronic sinusitis patient and an associated clinical tag; carrying out standardization processing on the CT image, wherein the standardization processing comprises gray level normalization, denoising and region-of-interest segmentation; a multi-task deep learning model is constructed, an improved 3D Re < s> Ne < t-50 > architecture is adopted by a typing sub-model to output an immune endotype classification result, and a severity evaluation sub-model segments a lesion area based on a U-Ne < t + + > structure and automatically calculates a severity level; integrating model output to generate individualized treatment suggestions; and superposing a labeling result through the thermodynamic diagram and embedding the labeling result into a hospital PACS system. Accurate typing and evaluation of chronic nasosinusitis are achieved, and diagnosis efficiency and clinical decision support capability are improved.

The invention belongs to the technical field of biological medicine, and relates to application of an OXTR agonist in preparation of a medicine for treating chronic sinusitis (CRS) and respiratory ciliary injury. CRS is treated based on targeted OXTR, and it is found that the OXTR agonist has an excellent treatment effect on promotion of nasal mucosa cilia regeneration and improvement of chronic sinusitis and can promote cilia repair, reduce infiltration of neutrophils and eosinophils and improve the inflammatory environment. In addition, an intranasal treatment dosage form aiming at OXTR is already applied to clinical application of nervous system diseases, the clinical application range of the medicine is expanded, practical feasibility is achieved by improving a better dosage form, and good industrialization prospects are achieved.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine compound for reducing recurrence of chronic nasosinusitis and a preparation method of the traditional Chinese medicine compound, and the traditional Chinese medicine compound is prepared from, by weight, 14-16 g of radix astragali, 8-10 g of fried radix scutellariae, 8-10 g of radix angelicae, 5-7 g of fructus xanthii, 5-7 g of flos magnoliae, 14-16 g of flos chrysanthemi indici, 11-13 g of fried fructus gardeniae, 5-7 g of radix angelicae sinensis, 5-7 g of flos carthami and 8-10 g of herba menthae. The traditional Chinese medicine composition can significantly improve clinical symptoms of patients with chronic nasosinusitis and reduce the recurrence rate, is good in safety, and does not find abnormal symptoms in clinical use. Meanwhile, the preparation process is simple to operate and suitable for industrial mass production. The raw medicinal materials selected by the traditional Chinese medicine composition are synergistic and complementary in nature and effect, inherit the holism concept of traditional Chinese medicine, emphasize that the traditional Chinese medicine composition emphasizes whole body treatment, plays a role together and inhibits infiltration of inflammatory cells while treating local parts, has small toxic and side effects, fully plays the advantages of treating chronic sinusitis and preventing relapse of the traditional Chinese medicine, relieves the pain of patients, and has a remarkable curative effect on treating chronic sinusitis. The life quality of patients is improved and the recurrence probability is reduced.

The invention provides a biomarker composition based on plasma metabonomics and application of the biomarker composition in early diagnosis of nasal extrinsic N / KT cell lymphoma, and relates to the technical field of biomarkers. According to the present invention, for the first time, it is provided that the 2-Methylbutyl beta-D-glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid and the 4-(octyloxyl) glucose acid can be adopted as the biomarkers for distinguishing the chronic sinusitis patient from the nasal knot external N / KT cell lymphoma patient, and the application of the 2-Methylbutyl beta-D-glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid and the 4-( According to the invention, a single-factor prediction model / combined factor prediction model NKTCL early diagnosis model AUCgt is constructed by taking the three biomarkers as characteristics and combining a random forest algorithm; 0.9, sensitivity gt; the specificity is gt; and the kit has relatively high accuracy, sensitivity and specificity for diagnosing the N / KT cell lymphoma outside the nasal knots, and is high in disease diagnosis and prediction capability. According to the method, stepped improvement of diagnosis efficiency is directly achieved through the synergistic effect of the multi-dimensional plasma metabonomics markers and algorithm suitability optimization, and a new normal form with high precision and clinical feasibility is provided for early screening of tumors.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a pharmaceutical composition for treating rhinitis and a preparation method and application thereof. The invention provides a pharmaceutical composition for treating rhinitis. The pharmaceutical composition is prepared from the following components in parts by mass: 12-15 parts of astragalus membranaceus, 9-12 parts of codonopsis pilosula, 9-12 parts of houttuynia cordata, 6-9 parts of divaricate saposhnikovia root, 9-12 parts of bighead atractylodes rhizome, 6-9 parts of radix bupleuri, 6-9 parts of ginger processed pinellia, 6-9 parts of fructus forsythiae, 6-9 parts of radix angelicae, 6-9 parts of fried semen armeniacae amarae, 6-9 parts of cocklebur fruit, 6-9 parts of isatis root, 6-9 parts of pogostemon cablin, 3-6 parts of rhodiola rosea, 2-4 parts of schizonepeta, 3-6 parts of dried ginger, 3-5 parts of Chinese date and 3-6 parts of liquorice. The composition provided by the invention is effective for both allergic rhinitis and chronic sinusitis, can relieve acute symptoms and improve chronic inflammation, and overcomes the defect of insufficient pertinence of the existing traditional Chinese medicine compound.

The invention discloses a traditional Chinese medicine preparation for treating chronic rhinitis and chronic nasosinusitis, and relates to the technical field of traditional Chinese medicine preparations. The felwort, the radices stellariae dichotomae, the wine-fried scutellaria baicalensis and the fried cape jasmine are used for treating middle-jiao and upper-jiao, the felwort and the radices stellariae dichotomae are used for clearing damp heat of middle-jiao and lower-jiao, and the fried cape jasmine, the wine-fried scutellaria baicalensis and the lalang grass rhizome are used for removing heat of the upper-jiao; fried cocklebur fruit, angelica dahurica and pogostemon cablin are strong in pungent power, fragrant and capable of opening orifices, and divaricate saposhnikovia root is used for ascending medicine Coix seeds and wax gourd kernels are used for removing dampness and turbidity. The traditional Chinese medicine has the effects of promoting blood circulation and removing blood stasis due to the fact that the peach kernels are independently matched, and the medicines are used together to achieve the effects of ascending lucidity, descending turbid, clearing heat and promoting diuresis.

The invention discloses application of a TGM2 inhibitor in treatment of chronic sinusitis with nasal polyp, asthma and fibrosis complications thereof. Through single cell transcriptome analysis, it is found that the TGM2 is specifically and highly expressed in a macrophage subset (Tgm < 2 + > macrophage) in a CRSwNP sample with asthma, and the TGM2 protein expression level is significantly and positively correlated with the clinical severity of diseases such as CRSwNP and asthma; animal experiments verify that pathological injuries of the nasal cavity and the lung of a Tgm2-knocked-out mouse type 2 inflammation model are relieved, the inflammation of the upper and lower respiratory tracts of the mouse and the fibrosis level of the lung tissue can be remarkably relieved by adopting a small molecule drug ERW1041E for nasal drop administration, and the safety is good; the invention provides a brand-new treatment strategy for patients with diseases related to type 2 inflammation, and has remarkable clinical transformation value and market prospect.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The invention relates to biodegradable intranasal system for the sustained-release of fluticasone propionate in the intranasal cavity, said system comprising a biodegradable polyester matrix that comprises the fluticasone propionate as the active ingredient to be released in the intranasal cavity, wherein the polyester is selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof; and a method for preparing said system. The invention also relates to a kit comprising the system of the invention and the means of insertion of the system into the nasal cavity. The invention further relates to fluticasone propionate for use for treating chronic rhinitis or chronic sinusitis, wherein the fluticasone propionate is in a form suitable for administration in the nasal cavity by means of the biodegradable intranasal system of the invention.

The present application belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating chronic rhinosinusitis in children, a compound preparation of the traditional Chinese medicine composition and application. The present application firstly provides an optimized traditional Chinese medicine formula, which takes Radix Saposhnikoviae, Magnolia flower and Xanthium fruit as monarch drugs, and the weight ratio of the monarch drugs is in the range of 1:6:1 to 1:2:1, which has a significant reducing effect on the expression level of inflammatory factors in chronic rhinosinusitis mice in vivo. Further, the present application provides a compound preparation of the traditional Chinese medicine formula for treating chronic rhinosinusitis in children combined with probiotics, and surprisingly finds that the compound preparation 2 has a more efficient and significant treatment effect than other compound preparations and the control group. The traditional Chinese medicine formula and the probiotics have a synergistic effect when combined in a weight ratio of 10:2. The present application has important significance in providing a preparation with the characteristics of no drug resistance, no side effect and fast effect for children with chronic rhinosinusitis.

The invention belongs to the technical field of biological medicines, and relates to an efficient affinity anti-human IL-33 monoclonal antibody and a preparation method thereof. The monoclonal antibody provided by the invention has good specificity and affinity, accurately targets a key cell factor IL-33, and effectively blocks a binding path between the key cell factor IL-33 and a receptor ST2. As a core factor mediating various inflammatory diseases, such as asthma, allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like, IL-33 is crucial in intervention of a regulation mechanism for disease treatment. The monoclonal antibody disclosed by the invention is novel in sequence, and provides a new thought for preparation of the medicine by inhibiting IL-33 mediated inflammatory reaction.

The invention belongs to the technical field of medicine, and discloses a medicinal sponge sheet for inhibiting growth of nasal polyp, the medicinal sponge sheet is composed of a medical grade absorptive gelatin sponge base material, triamcinolone acetonide and hydroxypropyl methyl cellulose, the medicinal sponge sheet adopts the medical gelatin base material with the porosity of 95% and the water absorption expansion rate of less than or equal to 30%, the size is 60mm * 20mm * 5mm, each sheet loads 60mg of triamcinolone acetonide, and the hydroxypropyl methyl cellulose is added into the medicinal sponge sheet. And 10% of hydroxypropyl methyl cellulose with the molecular weight of 35000 Da and the viscosity of 700 mPa.s is supplemented to construct a slow release system. Efficient and safe treatment of chronic nasosinusitis with nasal polyp is achieved through multi-dimensional innovative design, the three-dimensional interpenetrating pore structure of the medical gelatin base material provides an ideal carrier for drug release, 60%-70% of triamcinolone acetonide is continuously released within 7 days through the gradient slow release technology, a local high-concentration microenvironment is constructed, and the effect of treating chronic nasosinusitis with nasal polyp is achieved. The device directly acts on the polyp root to block an inflammation cascade reaction; in the formula, hydroxypropyl methyl cellulose is used as a core slow-release carrier.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The present invention relates to a composition comprising the combination of extracts from Centella asiatica or other members of the family Apiaceae, extract from the family Zingiberaceae, extract from the family Valerianaceae, extract from the family Capsicum, xylitol, sodium hyaluronate, glycerine, vitamins and minerals for treating and / or alleviating snoring, chronic sinusitis, cold, and / or obstructive sleep apnea in humans and animals.

The present disclosure relates generally to methods of treating chronic sinusitis with or without nasal polyp using antibodies specific for thymic stromal lymphopoietin (TSLP).

The invention discloses a chronic sinusitis full-automatic segmentation method based on deep learning and related equipment. The method comprises the following steps: acquiring paranasal sinus CT image data of a chronic sinusitis patient, wherein the paranasal sinus CT image data comprises paranasal sinus CT image data of patients with different genders, ages and disease course stages; dividing the paranasal sinus CT image data into a training verification set and a test set, and training an nnUNetV2 model based on the training verification set to obtain a chronic sinusitis region-of-interest segmentation model; and performing full-automatic segmentation of chronic sinusitis on CT image data of a target patient through the segmentation model of the region-of-interest of chronic sinusitis. The problems of low segmentation efficiency, high subjectivity and difficulty in precise segmentation of the chronic sinusitis region-of-interest caused by high complexity and individual variability of the anatomical structure of the nasal cavity and the paranasal sinus can be solved.

The present invention relates to a biodegradable intranasal system for the sustained release of fluticasone propionate in the nasal cavity, said system comprising a biodegradable polyester matrix containing fluticasone propionate as an active ingredient to be released into the nasal cavity, the polyester being selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof, a biodegradable intranasal system, and a method for preparing said system. The present invention also relates to a kit comprising the system of the present invention and means for inserting the system into the nasal cavity. The present invention further relates to fluticasone propionate for use in treating chronic rhinitis or chronic sinusitis, which is in a form suitable for intranasal administration by the biodegradable intranasal system of the present invention.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

Disclosed herein are antigen binding proteins, e.g. an antibody, which bind to IL-5, for use in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), wherein the nasal polyps score and / or mean nasal obstruction score is improved.

The invention discloses a medical drug-loading paranasal sinus stent as well as a preparation method and application thereof. The medical drug-loaded paranasal sinus stent comprises a nasosinusitis treatment drug and medical catalyst-free polycaprolactone loaded with the nasosinusitis treatment drug, the drug loading capacity of the medical drug-loading paranasal sinus stent is 2 to 20 weight percent; the 24-hour burst release rate of the medical drug-loading paranasal sinus stent is lt; the continuous release time is more than or equal to 4 weeks; wherein the medical catalyst-free polycaprolactone is prepared by carrying out ring opening polymerization on double ether bond oxalic acid amide dihydric alcohol serving as an initiator and caprolactone. According to the medical drug-loaded paranasal sinus stent, the risk of catalyst residue is completely eradicated from the source, the stent implantation safety is guaranteed, the controllable degradation performance and the drug slow release effect of the stent can meet the paranasal sinus postoperative repair requirement, and the medical drug-loaded paranasal sinus stent is suitable for in-vivo implantation and supporting of people or animals and has important prospects in the field of chronic nasosinusitis postoperative treatment.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

The invention discloses a chronic nasosinusitis auxiliary typing method based on radiomics data and related equipment. The method comprises the following steps: acquiring paranasal sinus radiomics data, clinical feature data and biological sample analysis result data of a chronic sinusitis patient; dividing the paranasal sinus radiomics data into a plurality of image clustering categories by adopting an unsupervised clustering algorithm, and associating clinical feature data and biological sample analysis result data corresponding to different image clustering categories respectively; and analyzing clinical feature data differences and biological sample analysis result data differences among different image clustering categories, and constructing a systematic mapping relationship between the image clustering categories and clinical pathological typing so as to carry out chronic sinusitis auxiliary typing. The problems that in typing research of chronic nasosinusitis, traditional intrinsic typing needs to depend on complex and expensive biological sample examination, generalizability is not high, and sampling cannot completely reflect individual heterogeneity of patients and is invasive can be solved.

The invention belongs to the technical field of biological medicines, and relates to a monoclonal antibody capable of being specifically combined with IL-33 as well as a preparation method and application thereof. The monoclonal antibody capable of being specifically bound with the IL-33 can be specifically bound with the IL-33 in a high-affinity mode, and therefore binding of the IL-33 and a receptor ST2 of the IL-33 is effectively blocked. IL-33 is an important cell factor, and plays a key role in the occurrence and development of various diseases, such as asthma, specific reactive / allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like. By blocking the combination of IL-33 and ST2, the antibody can inhibit inflammatory reactions mediated by IL-33, and a new strategy is provided for the treatment of these diseases.

Provided are combination dosing regimens comprising administering a monoclonal antibody, such as dupilumab, and hyaluronidase. Combinations and compositions containing the monoclonal antibody and hyaluronidase are provided. The dosing regimens and combinations with dupilumab are for treating or preventing allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis, eosinophilic esophagitis, and prurigo nodularis.

The invention discloses a medicinal moxa composition for preventing and treating chronic nasosinusitis and kidney stone co-disease. The medicinal moxa composition comprises asarum, gardenia jasminoides, agilawood and moxa. The medicinal moxa composition disclosed by the invention generates an external preparation with synergistic effects of smoke, medicinal gas and heating power through combustion. Volatile components of the four medicines are burnt to form a composite pharmacodynamic system which is absorbed by skin, mucous membrane and respiratory system to generate a unique treatment effect. The medicinal moxa composition can realize cold-warm balance, multi-target coordination, immunoregulation, anti-inflammatory action and diuresis metabolism regulation through the synergistic effect of heating power and volatile matters, so that the dual effects of preventing and treating nasosinusitis and kidney stone are achieved. Due to the external use characteristic, the traditional Chinese medicine composition can directly act on body surface acupuncture points and is conducted to related viscera through meridians and collaterals to form a treatment path from the outside to the inside.

This invention belongs to the field of nanomedicine delivery and immunotherapy technology, and provides a treatment for CD4-positive conditions including asthma, inflammatory bowel disease, and chronic sinusitis. + A CD4-targeting Runx3-siRNA nanodelivery system for T-cell-mediated chronic inflammatory diseases comprises lipid nanoparticles loaded with Runx3-siRNA and a CD4-targeting ligand coupled to the surface of the lipid nanoparticles. This system enables targeting of pathogenic CD4-mediated chronic inflammatory diseases. + T-cell-specific delivery and Runx3 gene silencing; lipid nanoparticles composed of ionic lipids, helper lipids, cholesterol, and PEG-modified lipids, with anti-CD4 antibodies anchored to the surface via maleimide-thiol coupling; this invention targets pathogenic CD4... + Specific delivery of T cells and silencing of the Runx3 gene solve the problems of side effects caused by non-specific immunosuppression and insufficient targeting of lipid nanoparticles.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.